WO2006049163A1 - 全血処理が可能なブラジキニンを発生させる体液処理材 - Google Patents
全血処理が可能なブラジキニンを発生させる体液処理材 Download PDFInfo
- Publication number
- WO2006049163A1 WO2006049163A1 PCT/JP2005/020102 JP2005020102W WO2006049163A1 WO 2006049163 A1 WO2006049163 A1 WO 2006049163A1 JP 2005020102 W JP2005020102 W JP 2005020102W WO 2006049163 A1 WO2006049163 A1 WO 2006049163A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- body fluid
- treatment material
- fluid treatment
- whole blood
- blood
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
Definitions
- Body fluid treatment material that generates bradykinin capable of whole blood treatment
- the present invention relates to a bodily fluid treatment material for obtaining a body fluid containing moderately brachycun, a method of generating brachycun in body fluid using the bodily fluid treatment material, and an appropriate amount using the bodily fluid treatment material.
- the present invention relates to a column for generating bradycun into body fluids, and particularly to a body fluid treatment material capable of processing whole blood.
- Bradykinin is a peptide having a biological activity of 9 amino acids discovered by Rochae Silva in 1949. Bradycun is released by the action of kallikrein on the high molecular weight kinogen, and the released bradycun is degraded by kininase II (same as angiotensin I converting enzyme).
- factor XII of the blood coagulation system is activated to become factor Xlla.
- This factor Xlla converts prekallikrein in the blood into force lykrain.
- this kallikrein acts on high-molecular kinogen in the blood and liberates bragicun.
- kallikrein that appears in this process has the property of activating factor XII.
- the increase in blood bracun concentration is caused by activation of the sputum factor when it comes into contact with the foreign body surface, but glass, celite, violin, collagen, etc. have been known for a long time. ing.
- it is known to be activated by stearic acid, ellagic acid, sulfate, plasmin, kallikrein and the like.
- factor XII is activated by contact with the surface of many negatively charged medical materials, and as a result, the concentration of bracicun increases.
- Bradykinin has a strong vascular smooth muscle relaxing action, and has a function of dilating blood vessels to lower blood pressure. This is because bradycun binds to the bradycun 2 receptor of vascular endothelial cells, contracts vascular endothelial cells, and increases capillary permeability. At that time, nitric oxide and nitrogen are produced, and arteriole smooth muscle Is thought to be due to relaxation and dilation of blood vessels.
- Hypertension which is a typical lifestyle-related disease, induces a stroke in which the risk of developing physical disability, fatal left ventricular failure, myocardial infarction, cerebral hemorrhage, cerebral infarction, or renal failure is very high. Is the most important risk factor.
- Angiotensin-converting enzyme inhibitors are commonly used as antihypertensive drugs for these hypertensive patients. However, in addition to angiotensin-converting enzyme inhibitory activity, angiotensin converting enzyme inhibitors produce vasodilator nitric oxide in endothelial cells. It also suppresses the activity of kininase II, which hydrolyzes bradycun, and slows the degradation of brazicun, thereby exhibiting a hypotensive effect.
- arteriosclerosis is closely related to hypertension.
- high pressure is constantly applied to the arteries due to high blood pressure, the arterial wall is damaged, and this fat damage penetrates the blood and causes arteriosclerosis.
- blood vessels become narrower and blood flow becomes worse, and in order to improve it, a vicious circle is created in which the heart strengthens pulsation and blood pressure rises.
- arteriosclerosis a disease causing blockage of peripheral blood vessels is called obstructive arteriosclerosis.
- peripheral blood vessels become narrower and obstructed, resulting in poor peripheral blood circulation, resulting in symptoms such as sensation of limbs, numbness, intermittent claudication, resting pain, ulcers, and gangrene. Lead to cutting. For this reason, it is expected that blood flow will be improved by the action of bradycun having a vasodilatory effect, and these symptoms will be improved.
- brazicun when the blood concentration increases due to the powerful vasodilatory action of brazicun, it may cause anaphylaxis-like symptoms such as rapid blood pressure drop and nausea.
- blood purification therapy by extracorporeal circulation which has been actively performed in recent years, is a treatment to remove the blood pathogenic agent, but at that time, certain medical materials and blood Z plasma come into contact with each other. This is a problem that may cause excessive production of anaphylaxis-like symptoms.
- Patent Document 1 the above symptom appears when the plasma concentration of brazicun is more than OOOpgZml.
- Patent Document 1 and Patent Document 2 describe an adsorbent that uses hydrophobicity for the purpose of removing bracyne from blood. It is aimed at.
- the conventional technique there is only a method of removing bradykinin in order to generate bradykinin in the blood in whole blood processing, and blood pressure is increased by vasodilatory action without causing anaphylactoid symptoms.
- the development of a whole blood treatment method that generates brazicun to such an extent that it lowers or improves blood flow in patients with obstructive arteriosclerosis has been desired.
- Patent Document 1 JP-A-6-296861
- Patent Document 2 JP-A-6-296864
- the present invention provides a body fluid treatment material characterized by generating bradycun in a body fluid to such an extent that blood pressure can be reduced or blood flow can be improved without significant side effects, and A method for generating brachycun in body fluids using this body fluid treatment material, and a column for generating brazilcum using this body fluid treatment material, which minimizes the loss of blood cells without losing useful substances such as albumin as much as possible.
- the present invention provides a body fluid treatment material and a column, which are characterized by being capable of processing whole blood safely to a limited extent.
- the present inventors have eagerly developed a body fluid treatment material capable of processing whole blood without losing useful substances such as albumin as much as possible and generating a controlled amount of bradycun in body fluids, particularly blood.
- a body fluid treatment material is obtained by immobilizing tributophan derivative and polyion compound in a water-insoluble porous carrier, and a certain amount of polyion compound is immobilized.
- a body fluid treatment material that has a specific molar ratio between the amount of immobilized tributophane derivative and the amount of immobilized polyaion compound.
- the present inventors have found that this is a body fluid treatment material that can safely treat whole blood by minimizing the loss of blood cells.
- the first invention of the present invention is a body fluid treatment material comprising a water-insoluble porous carrier fixed with a tributophane derivative and a polyion compound, Compound The amount of immobilization is between 0.10 / z mol and less than 1.5 / z mol per ml of wet fluid treatment material, and the amount of tryptophan derivative immobilized per ml of wet fluid treatment material and polyaunity
- the present invention relates to a body fluid treatment material for generating a bloodycun capable of processing whole blood having a molar ratio of 1 to 70 with respect to the amount of the compound fixed amount.
- the second invention relates to a method for generating brachycun, wherein the body fluid treatment material is brought into contact with body fluid.
- the third invention is characterized in that a body fluid treatment material for generating brachycun is filled in a container having an inlet and an outlet for the liquid and provided with means for preventing the body fluid treatment material from flowing out of the container.
- the present invention relates to a column that generates bradykinin capable of processing whole blood.
- the present invention it is possible to obtain a bodily fluid in which bradycine is appropriately generated directly in a bodily fluid, particularly whole blood, without losing useful substances such as albumin as much as possible.
- the present invention is effective as a method for lowering blood pressure in hypertensive patients or improving blood flow in patients with arteriosclerosis, particularly obstructive arteriosclerosis.
- FIG. 1 is a schematic cross-sectional view of an embodiment of a column for generating brachycun according to the present invention.
- FIG. 2 is a graph showing the results of examining the relationship between flow velocity and pressure loss using three types of gels.
- the body fluid in the present invention refers to blood, plasma, or serum.
- the poly-on compound in the present invention refers to a plurality of er-on functional groups in a molecule.
- the terionic functional group in the present invention means a functional group that is neutral in pH and negatively charged, such as a carboxyl group, a sulfonic acid group, a sulfate ester group, and a phosphate ester group.
- sulfate groups are particularly preferred because they have the ability to control the amount generated, even though carboxyl groups, sulfonic acid groups, and sulfate groups are preferred in terms of the ability to generate bradycun appropriately.
- poly-on compounds include polyacrylic acid, polybulusulfonic acid, polystyrene sulfonic acid, polyglutamic acid, polyaspartic acid, polymethacrylic acid, polyphosphoric acid, and styrene maleic acid.
- Synthetic poly-on compounds such as polymers, synthetic acidic polysaccharides such as dextran sulfate and carboxymethyl cellulose, and biological acid mucopolysaccharides having sulfate ester groups such as chondroitin sulfate, dermatan sulfate, and ketalan sulfate , Acidic mucopolysaccharides having N-sulfonic acid groups and sulfate ester groups such as heparin and heparan sulfate, polysaccharides having biological functional groups such as chondroitin and phosphomannan, and deoxyribonucleic acid and ribonucleic acid Examples include nucleic acids derived from living organisms such as nucleic acids. But it is not limited to.
- the molecular weight of the poly-on-ionic compound is 1000 or more, particularly 3000 or more.
- the upper limit of the molecular weight of the polyon-ionic compound is not particularly limited, but is preferably 1 million or less from the practical viewpoint.
- Typical methods include (1) Polyon-on (2) Polyanionic properties by a chemical method via a functional group of the water-insoluble porous carrier by the method of covalently bonding the compound to the surface of the water-insoluble porous carrier by a graft method using radiation or electron beam. There are methods for covalently bonding compounds.
- the present invention is a body fluid treatment material obtained by immobilizing a poly-on compound and a tributophane derivative
- the poly-on is chemically formed via a functional group.
- the method of covalently bonding a sex compound is the simpler and preferred method for the present invention because the fixation of the tributophan derivative can be carried out in the same manner.
- the tributophane derivative in the present invention refers to a compound having a structure similar to that of trybutophane having an indole ring such as tryptamine or tryptophanol, tryptophan esters such as trybutophane, tributofaneethyl ester, tryptophan methyl ester, or the like.
- tryptophan derivatives may be any of L-form, D-form, DL-form, or a mixture thereof. Furthermore, it may be a mixture of two or more tributophan derivatives.
- L-tributophane is a natural amino acid among the tributophanes that are preferred for safety, because of their abundant safety data, and because they are the cheapest and most readily available. It is most preferably used practically.
- a method for fixing the tributophan derivative in the present invention a method of covalently binding the tributophan derivative by a chemical method through a functional group of a water-insoluble porous carrier is preferably used.
- the amount of immobilization of the polyon-ion compound in the present invention is not less than 0.1011101 and not more than 1.5 mol per ml of body fluid treatment material in a wet volume, and the amount of immobilized tryptophan derivative and It is necessary that the molar ratio with the amount of the on-state compound fixed amount is 1 or more and 70 or less.
- the amount of tributophane derivative-fixed amount and the amount of polya-on compound-fixed compound amount is a value calculated by the following equation.
- TRZPA ratio number of moles of immobilized tryptophan derivative per ml of wet body fluid treatment material Number of polyion-immobilized immoles per ml of body fluid treatment material of Z wet volume
- the present inventors are surprising.
- the fixed amount of polyon-ion compound is adjusted to 0.10 per ml of wet body fluid treatment material.
- the fixed amount of the poly-on compound is from 0.10 mol to 1.5 mol per lml (wet volume) of the body fluid treatment material. If this amount of immobilization is reduced to less than 0.10 / z moU, bradykinin generation is low and the permeability of leukocytes and platelets deteriorates, and the number of leukocytes in pooled blood decreases when whole blood perfusion is performed. To do. On the other hand, when the amount is more than 1.5 mol, a large amount of bracicun is generated even if the tributophane derivative is fixed.
- the fixed amount of the polyon-ion compound is such that it has an appropriate amount of brazicun generation and good blood cell permeability, preferably 0.12 / z mol or more and 1.O / z mol or less, Most preferably, it is 0.15 mol or more and 0.50 mol or less.
- the molar ratio (TRZPA ratio) between the amount of tributophane derivative immobilized and the amount of immobilized polya-one compound (TRZPA ratio) is 1 or more and 70 or less.
- TRZPA ratio is less than 1
- a large amount of brachycun is generated.
- TRZPA ratio is greater than 70
- bradykinin is hardly generated.
- the permeability of white blood cells and platelets gradually deteriorates, and the number of white blood cells in pooled blood decreases when whole blood perfusion is performed.
- Point power capable of exhibiting moderate generation of brazicun and good blood cell permeability preferably 5 or more and 60 or less, and most preferably 10 or more and 50 or less.
- the volume of the wet body fluid treatment material in the present invention is determined as follows.
- the bodily fluid treatment material is transferred to a measuring container such as a graduated cylinder as a slurry immersed in water, and the slurry-like bodily fluid treatment material in the measuring container is allowed to settle naturally. After this, lay a rubber mat or the like so that the measuring container does not break, and lighten the measuring container 5 to 10 cm lightly about 5 to 10 times in the vertical direction. Add vibration by striking it (to the extent that it does not force up). After standing for at least 15 minutes, read the sedimentation volume of the body fluid treatment material. This vibration and stationary operation is repeated, and the stage where the sedimentation volume of the body fluid treatment material does not change is defined as the sedimentation volume of the body fluid treatment material in the wet state.
- the present invention as a method for measuring the amount of fixed ions of a polyionic compound, the content of an element contained in a polyionic compound in a body fluid treatment material is quantified (for example, In the case of stransulfuric acid, the sulfur content of the body fluid treatment material is quantified.)
- the method using a dye solution is simple, but can accurately measure the amount of immobilized polyanion compound.
- the polyone-on compound is dextran sulfate or polyacrylic acid
- the compound has a property of binding to toluidine blue. This makes it possible to measure the amount of the fixed amount of Toiser Blue when the Toluidine Blue solution and the body fluid treatment material are brought into contact with each other very easily.
- the fixed amount of the tributophane derivative in the present invention utilizes the property of coloring when an aldehyde such as p-dimethylbenzaldehyde is condensed with the indole ring present in the molecule of the tryptophan derivative under strongly acidic conditions.
- an aldehyde such as p-dimethylbenzaldehyde
- the indole ring existing in the molecule of the tributophan derivative is excited by light at around 280 nm, it is quantified using the property of emitting fluorescence having a maximum at around 350 ⁇ m, or the carrier itself contains nitrogen.
- the carrier itself contains nitrogen.
- it can also be measured by quantifying the nitrogen content in the body fluid treatment material as shown in the specific method in Example 1.
- the water-insoluble porous carrier in the present invention is solid at room temperature and normal pressure, is insoluble in water, and has pores of an appropriate size, that is, has a porous structure.
- a spherical shape or a granular shape is more preferably used because of the ease of handling force that can effectively use any of a spherical shape, a granular shape, a flat membrane shape, a fibrous shape, a hollow fiber shape, and the like.
- the average particle size of the carrier is large! /, although considering that the body fluid treatment material of the present invention can be treated with whole blood, bradycun In terms of generation, it is better that the average particle size is smaller because the contact area between the body fluid and the treatment material becomes larger.
- the average particle size of the body fluid treatment material capable of generating whole blood treatment and moderate bracyn is 100 ⁇ m or more and 1000 ⁇ m or less.
- the point force that can control the occurrence of the occurrence is more preferably 200 ⁇ m or more and 800 ⁇ m or less, and most preferably 400 ⁇ m or more and 600 ⁇ m or less.
- the exclusion molecular weight of the globular protein of the water-insoluble porous carrier is preferably 5 X 10 5 or more. It is used well. Exclusion limit molecular weight is described in the book (size exclusion chromatography, written by Sadao Mori, Kyoritsu Shuppan). When a sample with various molecular weights flows in size exclusion chromatography, it penetrates into the pores. This is the molecular weight of the smallest molecular weight that cannot be excluded. If the molecular weight of the globular protein is less than 5 X 10 5 , the amount of brazicun is increased and it is not practical.
- the exclusion molecular weight of the globular protein of the water-insoluble porous carrier in the present invention is preferably 5 ⁇ 10 5 or more and 1 ⁇ 10 8 or less, more preferably 1 ⁇ from the viewpoint of controlling the amount of brazicun generated. 10 6 or more and 1 ⁇ 10 8 or less, more preferably 2 ⁇ 10 6 or more and 1 ⁇ 10 8 or less.
- the water-insoluble porous carrier in the present invention preferably has a functional group that can be used for binding in order to immobilize the polyone-on compound and the tryptophan derivative.
- a functional group that can be used for binding in order to immobilize the polyone-on compound and the tryptophan derivative.
- functional groups include amino groups, amide groups, carboxyl groups, acid anhydride groups, succinimide groups, hydroxyl groups, thiol groups, aldehyde groups, halogen groups, epoxy groups, silanol groups, and tresyl groups. However, it is not limited to these.
- the water-insoluble porous carrier may be activated by a method such as a halogen cyanide method, an epichlorohydrin method, a bis epoxide method, or a bromoacetyl bromide method.
- a method such as a halogen cyanide method, an epichlorohydrin method, a bis epoxide method, or a bromoacetyl bromide method.
- the epichlorohydrin method is particularly preferably used.
- the strength of the water-insoluble porous carrier of the present invention it is not preferable that the strength is soft and it is easily broken.
- the body fluid treatment material is sufficient to prevent the body fluid treatment material from being consolidated.
- Those having mechanical strength (hard) are preferred.
- the term “hard” as used herein refers to the relationship between the pressure loss and the flow rate when a body fluid treatment material is uniformly packed in a cylindrical column as shown in the reference example, and an aqueous liquid is flowed, at least 0.3 kgf / cm 2. The one that has a straight line relationship.
- the material of the water-insoluble porous carrier in the present invention is not particularly limited, but an organic carrier having a polysaccharide power such as cellulose, cellulose acetate, dextrin, polystyrene, styrene-dibutylbenzene copolymer, polyacrylamide, Polyacrylic acid, polymethacrylic acid, poly Synthetic high molecules such as reacrylic acid ester, polymethacrylic acid ester, and polybutyl alcohol are representative examples. These include polymer materials having hydroxy groups such as hydroxyethyl methacrylate and graft copolymers such as copolymerization of a monomer having a polyethylene oxide chain and another polymerizable monomer. Or the like. Of these, cellulose and polybutyl alcohol are preferred for practical use because they can easily introduce active groups onto the surface of a synthetic polymer force carrier such as polyalcohol.
- a synthetic polymer force carrier such as polyalcohol.
- a carrier having cellulose strength is most preferably used.
- the carrier that has cellulose strength is (1) toughened with relatively high mechanical strength, so it will be consolidated even if the body fluid flows at a high flow rate when packed in a column that is less likely to be broken or produce fine particles. It is difficult to flow body fluid at a high flow rate, and (2) has superior points such as higher safety than synthetic polymer carriers, and as a water-insoluble porous carrier in the present invention. It can be used most suitably.
- Anticoagulants for extracorporeal circulation treatment using the column of the present invention include heparin, low molecular weight hetero ⁇ phosphorus, nafamostat mesylate, gabexate mesylate, argatroban, and sodium citrate solution,
- a citrate-containing anticoagulant such as acid citrate dextrose solution (ACD solution) or citrate phosphate dextrose solution (CPD solution) may be used.
- ACD solution acid citrate dextrose solution
- CPD solution citrate phosphate dextrose solution
- citrate-containing anticoagulant, heparin, low molecular heparin, and nafamostat mesylate are particularly preferred anticoagulants from the viewpoint of whole blood treatment.
- a body fluid is taken out and stored in a bag, etc., and a body fluid treatment material is mixed therewith to generate brachycun, and then the body fluid treatment material is filtered to obtain a body fluid in which brachykun is generated, Create a column filled with bodily fluid treatment material into a container equipped with a filter fitted to the outflow port that has a bodily fluid inflow port and outflow port, through which bodily fluid passes but does not pass bodily fluid treatment material, etc. There is.
- the column of the present invention has an inlet and an outlet for bodily fluids, and the body fluid treatment material of the present invention is filled in a container equipped with a filter that passes through the body fluid but does not pass the bodily fluid treatment material at the outflow port. Do it.
- the capacity of the column of the present invention is required to be 100 ml or more in view of generating an appropriate amount of brachycun.
- the volume of the column There is no limit on the volume of the column, but if the volume is too large, a large amount of brachycun is generated, and if too much blood is taken out of the body, there is a risk of lowering blood pressure. Even if it is incorporated into other blood purification circuit such as hemodialysis, the volume is preferably 1000ml, more preferably 800ml or less. The extracorporeal circulation of blood does not become extremely large and blood goes out of the body. From the viewpoint of preventing as much as possible a decrease in blood pressure that may occur, it is most preferably 400 ml or less.
- FIG. 1 is a schematic sectional view of one embodiment.
- 1 is a body fluid inlet
- 2 is a body fluid outlet
- 3 is a body fluid treatment material that generates bradycun appropriately
- 4 and 5 are meshes
- 6 is a column
- 7 is brasicun.
- the column for generating brachycun according to the present invention is not limited to such a specific example, but has a liquid inlet and outlet, and a container having means for preventing the body fluid treatment material from flowing out of the container.
- the shape is not particularly limited as long as it is filled with a body fluid treatment material that moderately generates bracyn.
- Dextran sulfate (Sulfur content: about 18%, molecular weight: about 4000) 35.4 g of dextran sulfate aqueous solution prepared by dissolving in 100 ml of water was prepared, and 220 ml of epoxy cellulose bead wet in water was prepared. After making alkaline with NaOH aqueous solution, the mixture was reacted at 45 ° C for 3 hours. After the reaction, the beads were thoroughly washed with water and saline, and then a solution prepared by dissolving 3.68 g of L-tributophane in 120 ml of dilute aqueous NaOH was prepared and reacted at 55 ° C. for 6 hours. Thereafter, the beads were sufficiently washed with water and a saline solution to obtain dextran sulfate and tributophane-fixed cell mouth beads (A).
- This A was placed in a 0.2 ml test tube, 3 ml of healthy human blood coagulated with 5 units of heparin added to 1 ml of blood, and shaken at 37 ° C for 10 minutes. As a result of measuring the brazikun concentration in the supernatant by the radioimmunoassay method, it was 291 pgZml.
- the amount of the tryptophan-fixed amount of A was determined from the nitrogen content of the body fluid treatment material. In other words, lml of A was thoroughly washed with water, dried under reduced pressure at 60 ° C for 6 hours or more, and then quantified with a trace total nitrogen analyzer. As shown in Table 1, A's tribute fan fixing amount is 10.0 m. It was olZ ml.
- the amount of dextran sulfate immobilized on A was measured by utilizing the affinity of dextran sulfate and toluidine blue. That is, add about 100 ml of toluidine blue (Basic Blue 17 (Tokyo Kasei)) solution adjusted to about 90 mgZl to 3 ml of A, stir for 10 minutes, and let stand, and then add the supernatant toluidine blue by absorbance at 630 nm. Quantified and calculated from the amount of decrease. As shown in Table 1, the amount of dextran sulfate immobilized on A was 0.20 / z molZml, and the TRZPA ratio was 50.0.
- a dextran sulfate aqueous solution prepared by dissolving 7.2 g of dextran sulfate as in Example 1 in 20 ml of water was prepared, and 48 ml of epoxidized cellulose beads in a state of being wetted with water were prepared and made alkaline with an aqueous NaOH solution. Thereafter, the mixture was reacted at 45 ° C for 6 hours. After the reaction, the beads were thoroughly washed with water and brine, and then a solution prepared by dissolving 0.76 g of L-tryptophan in 25 ml of dilute aqueous NaOH was prepared and reacted at 50 ° C. for 8 hours.
- the beads were sufficiently washed with water and saline to obtain dextran sulfate and tributophane-fixed cellulose cellulose beads (B).
- B dextran sulfate and tributophane-fixed cellulose cellulose beads
- the amount of tryptophan immobilized in B was 5.1 ⁇ mol / ml
- the amount of dextran sulfate immobilized was 0.28 molZml
- the TRZPA ratio was 18.2.
- Example 2 B was packed in a column, and 40 ml of healthy human blood was circulated for 2 hours.
- the number of blood cells in the pooled blood before and after circulation is as shown in Table 2, and all blood cells showed good permeability.
- the beads were sufficiently washed with water and saline to obtain dextran sulfate and tributophane-fixed cellulose cellulose beads (C).
- C dextran sulfate and tributophane-fixed cellulose cellulose beads
- Example 1 Further, as in Example 1, C was packed in a column, and 40 ml of healthy human blood was circulated for 2 hours.
- the number of blood cells in the pooled blood before and after circulation is as shown in Table 2, and all blood cells showed good permeability.
- Example 1 place 0.2 ml of physiological saline in place of A in a test tube, add 3 ml of blood to 1 ml of blood and add 3 ml of normal blood anticoagulated for 10 minutes at 37 ° C. Shake. As a result of measuring the concentration of bracicin in the supernatant by the radioimmunoassay method, it was found to be 22 pg Z ml.
- Dextran sulfate and tryptophan-immobilized cellulose beads (Example 2) except that the reaction time of dextran sulfate was changed from 6 hours to 0.5 hour and the amount of dextran sulfate was changed from 19.8 g to 7.2 g. D) was obtained.
- the amount of D immobilized on tryptophan was 7.3 ⁇ mol / ml
- the amount of dextran sulfate immobilized was 0.07 ⁇ mol / ml
- the TR / PA ratio was 104.3.
- Example 1 Further, as in Example 1, D was packed in a column, and 40 ml of healthy human blood was circulated for 2 hours.
- the number of blood cells in the pooled blood before and after circulation is as shown in Table 2. Red blood cells showed good permeability, while white blood cells and platelets decreased to 66% and 63% before and after circulation, respectively. Somewhat bad.
- Example 1 As in Example 1, take this E in a 0.2 ml test tube, add 3 units of heparin to 1 ml of blood, and add 3 ml of anticoagulated healthy human blood, and shake at 37 ° C for 10 minutes. I let you. As a result of measuring the brachycun concentration of the supernatant by the radioimmunoassay method, it was 32 pgZml.
- Example 1 E was packed in a column, and 40 ml of healthy human blood was circulated for 2 hours.
- the blood counts of the pooled blood before and after circulation are as shown in Table 2, and red blood cells and platelets showed good passage.
- the amount of polyanion compound immobilized is between 0.10 / xmol and less than 1.5 / zmol per ml, and the amount of tryptophan immobilized and the polyanion compound
- the bradykinin concentration increased.
- Comparative Example 2 and Comparative Example 3 are outside these ranges. In this case, no treatment material was added! /, And no generation of brachycun was observed as in Comparative Example 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006542398A JPWO2006049163A1 (ja) | 2004-11-05 | 2005-11-01 | 全血処理が可能なブラジキニンを発生させる体液処理材 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-322018 | 2004-11-05 | ||
JP2004322018 | 2004-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006049163A1 true WO2006049163A1 (ja) | 2006-05-11 |
Family
ID=36319168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/020102 WO2006049163A1 (ja) | 2004-11-05 | 2005-11-01 | 全血処理が可能なブラジキニンを発生させる体液処理材 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2006049163A1 (ja) |
WO (1) | WO2006049163A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009240491A (ja) * | 2008-03-31 | 2009-10-22 | Asahi Kasei Kuraray Medical Co Ltd | 体液浄化システムの作動方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6090039A (ja) * | 1983-10-21 | 1985-05-21 | Asahi Chem Ind Co Ltd | 血液浄化吸着体 |
JPH07136256A (ja) * | 1993-11-17 | 1995-05-30 | Asahi Medical Co Ltd | 血管閉塞性疾患血漿の血漿粘度低下方法及びその装置 |
WO2004098680A1 (ja) * | 2003-05-08 | 2004-11-18 | Kaneka Corporation | 全血処理が可能な低密度リポ蛋白およびフィブリノーゲンの吸着材、及び吸着器 |
-
2005
- 2005-11-01 WO PCT/JP2005/020102 patent/WO2006049163A1/ja active Application Filing
- 2005-11-01 JP JP2006542398A patent/JPWO2006049163A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6090039A (ja) * | 1983-10-21 | 1985-05-21 | Asahi Chem Ind Co Ltd | 血液浄化吸着体 |
JPH07136256A (ja) * | 1993-11-17 | 1995-05-30 | Asahi Medical Co Ltd | 血管閉塞性疾患血漿の血漿粘度低下方法及びその装置 |
WO2004098680A1 (ja) * | 2003-05-08 | 2004-11-18 | Kaneka Corporation | 全血処理が可能な低密度リポ蛋白およびフィブリノーゲンの吸着材、及び吸着器 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009240491A (ja) * | 2008-03-31 | 2009-10-22 | Asahi Kasei Kuraray Medical Co Ltd | 体液浄化システムの作動方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006049163A1 (ja) | 2008-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4578405B2 (ja) | 全血処理が可能な低密度リポ蛋白およびフィブリノーゲンの吸着材、及び吸着器 | |
ES2647577T3 (es) | Uso de heparina y carbohidratos para tratar el cáncer | |
JP2001299904A (ja) | フィブリノーゲンおよび/またはフィブリンの濃度を減少させるための吸着剤、吸着装置の製造のための吸着剤の使用、および吸着剤を有する吸着装置 | |
JP2001316420A (ja) | フィブリノーゲンおよび/またはフィブリンの濃度を減少させるための吸着剤の製造法、吸着剤、および吸着装置の製造のための吸着剤の使用 | |
WO2006049163A1 (ja) | 全血処理が可能なブラジキニンを発生させる体液処理材 | |
JPH01171638A (ja) | 血清アミロイドa蛋白用吸着体 | |
JP3285441B2 (ja) | 血管閉塞性疾患血漿の血漿粘度低下用吸着材及び血漿粘度低下装置 | |
JPS6090039A (ja) | 血液浄化吸着体 | |
JPH02149341A (ja) | 血清アミロイドp蛋白用吸着体 | |
JPS6319214B2 (ja) | ||
JP5036315B2 (ja) | 血液接触材料の改質方法、及び顆粒球活性化が抑制された血液接触材料 | |
JP4834812B2 (ja) | 体外循環医療カラム用補助用具 | |
JPS63232845A (ja) | 低比重リポ蛋白質の吸着材およびその製造方法 | |
JP3157026B2 (ja) | 血液浄化用吸着材 | |
JP4141224B2 (ja) | 低密度リポ蛋白およびフィブリノーゲンの吸着材、及びその吸着器 | |
JP3741319B2 (ja) | 低キニン血漿の製造装置と吸着材 | |
JP4443309B2 (ja) | フィブリノゲン吸着剤iii | |
JPH06233816A (ja) | 血液浄化吸着材 | |
JPH0258939B2 (ja) | ||
JPH105330A (ja) | 細胞由来放出因子の吸着体、それを用いる吸着除去装置および吸着除去方法 | |
JPS59139937A (ja) | 低比重リポ蛋白吸着材 | |
RU2098140C1 (ru) | Способ проведения экстракорпоральной иммуносорбции | |
JP5214857B2 (ja) | 多孔質基材 | |
JPH06237995A (ja) | 血液浄化吸着材 | |
JP2001218839A (ja) | ヘパリン吸着体、及びそれを用いたヘパリンの除去方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006542398 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05805425 Country of ref document: EP Kind code of ref document: A1 |